Literature DB >> 17387157

Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel.

Kimberley Clawson Stone1, Ron Dagan, Adriano Arguedas, Eugene Leibovitz, Elaine Wang, Roger M Echols, Nebojsa Janjic, Ian A Critchley.   

Abstract

Faropenem was tested against 1,188 middle ear fluid pathogens from children in Israel and Costa Rica. Against Streptococcus pneumoniae and Haemophilus influenzae, faropenem was the most active beta-lactam, with activity that was similar to or greater than of the other oral antimicrobial classes studied. Faropenem was also active against Moraxella catarrhalis and Streptococcus pyogenes.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17387157      PMCID： PMC1891012          DOI： 10.1128/AAC.00049-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters.

Authors:  M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2000-05       Impact factor: 2.129

2.  Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  K Ubukata; Y Shibasaki; K Yamamoto; N Chiba; K Hasegawa; Y Takeuchi; K Sunakawa; M Inoue; M Konno
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Short report: antimicrobial susceptibility and genetic characteristics of Haemophilus influenzae isolated from patients with respiratory tract infections between 1987 and 2000, including beta-lactamase-negative ampicillin-resistant strains.

Authors:  L Qin; H Watanabe; N Asoh; K Watanabe; K Oishi; T Mizota; T Nagatake
Journal:  Epidemiol Infect       Date:  2006-09-06       Impact factor: 2.451

4.  Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis.

Authors:  John Upchurch; Michael Rosemore; Robert Tosiello; Steven Kowalsky; Roger Echols
Journal:  Otolaryngol Head Neck Surg       Date:  2006-10       Impact factor: 3.497

5.  Molecular evolution of beta-lactam-resistant Haemophilus influenzae: 9-year surveillance of penicillin-binding protein 3 mutations in isolates from Japan.

Authors:  Yumiko Sanbongi; Takahisa Suzuki; Yumi Osaki; Nami Senju; Takashi Ida; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.

Authors:  Stephen G Jenkins; David J Farrell; Manish Patel; Bruce S Lavin
Journal:  J Infect       Date:  2005-06-13       Impact factor: 6.072

7.  Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Ian A Critchley; James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Kate Murfitt; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults.

Authors:  Ralf Siegert; Olof Berg; Pierre Gehanno; Alberto Leiberman; Jonas Laimutis Martinkenas; Paul Nikolaidis; Pierre Arvis; Melody Alefelder; Peter Reimnitz
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-10-11       Impact factor: 2.503

9.  In vitro activities of levofloxacin and comparable agents against middle ear fluid, nasopharyngeal, and oropharyngeal pathogens obtained from Costa Rican children with recurrent otitis media or failing other antibiotic therapy.

Authors:  Carolina Soley; Adriano Arguedas; Wendy Porras; Silvia Guevara; Cecilia Loaiza; Alexandra Pérez; Guillermo Rincón; Malka Schultz; Jorge Arguedas; Roberto Brilla
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

10.  Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae.

Authors:  Henri Dabernat; Catherine Delmas; Martine Seguy; Roseline Pelissier; Genevieve Faucon; Safia Bennamani; Christophe Pasquier
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  4 in total

1.  Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.

Authors:  Klaudia Kosowska-Shick; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

2.  National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.

Authors:  Ian A Critchley; Steven D Brown; Maria M Traczewski; Glenn S Tillotson; Nebojsa Janjic
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

3.  In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

Review 4.  Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge.

Authors:  Sumitha Nayak; Uday Pai; Amita Birla
Journal:  Cureus       Date:  2022-04-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.